Anemia in patients with chronic inflammatory bowel disease

Prevalence of iron deficiency anemia and iron deficiency in a pediatric population with inflammatory bowel disease

“…Recently, its gastrointestinal side-effects, slow onset of action and negative impact on disease activity gave rise to the use of intravenous formulations [2,5,6,9,[13][14][15]. There have been some concerns regarding the safety of these preparations in the pediatric population, mainly with dextran formulations which carry increased risk of anaphylaxis [6,8,9,15,16].…”

Anemia in Inflammatory Bowel Diseases in Children

“…После лечения анемии параметры обмена железа контролируются каждые 3 мес на протяжении 1 года, затем 1 раз в 6-12 мес. Рецидивирующий ане-мический синдром может свидетельствовать о сохра-нении эндоскопической активности ВЗК при наличии клинической ремиссии и низкого уровня С-реактивного белка [37].…”

“…Должен осущест-вляться не только контроль клинического анализа крови, но и биохимических параметров обмена железа. В слу-чае дефицита железа рекомендуется корректировать терапию парентеральными препаратами железа [37].…”

Stimulating erythropoiesis in inflammatory bowel disease associated anemia

“…However, EPO should be reserved for symptomatic patients who may otherwise require blood transfusions, who have not responded to intravenous iron, and in whom aggressive management of IBD (including immunosuppressive therapy) has not suppressed the mucosal inflammation. EPO is an adjunct and not an alternative to appropriate treatment of IBD [77] . Several issues remain to be resolved including the use of EPO for prevention of anemia, the target hemoglobin levels, and the immunologic role of EPO in the setting of chronic bowel inflammation.…”